Production (Stage)
Gemina Laboratories Ltd.
GLAB
CNSX
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.00% | -1.07% | -25.28% | -18.79% | -2.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.41% | -26.42% | -42.19% | -44.92% | -38.93% |
| Operating Income | 13.65% | 26.42% | 42.19% | 44.92% | 38.93% |
| Income Before Tax | 10.72% | 23.92% | 47.27% | 43.44% | 38.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.72% | 23.92% | 47.27% | 43.44% | 38.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.72% | 23.92% | 47.27% | 43.44% | 38.16% |
| EBIT | 13.65% | 26.42% | 42.19% | 44.92% | 38.93% |
| EBITDA | 13.51% | 26.41% | 42.32% | 45.12% | 39.10% |
| EPS Basic | 11.70% | 25.47% | 50.44% | 48.26% | 47.02% |
| Normalized Basic EPS | 11.72% | 25.45% | 50.70% | 48.55% | 46.99% |
| EPS Diluted | 11.70% | 25.47% | 50.44% | 48.26% | 47.02% |
| Normalized Diluted EPS | 11.72% | 25.45% | 50.70% | 48.55% | 46.99% |
| Average Basic Shares Outstanding | 1.42% | 1.60% | 5.54% | 9.22% | 15.77% |
| Average Diluted Shares Outstanding | 1.42% | 1.60% | 5.54% | 9.22% | 15.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |